Transitions in decision-making authority at the end of life: a problem of law, ethics and practice in deceased donation.

Decision-making Donation/Procurement of Organs/Tissues End-of-life Ethics Law

Journal

Journal of medical ethics
ISSN: 1473-4257
Titre abrégé: J Med Ethics
Pays: England
ID NLM: 7513619

Informations de publication

Date de publication:
02 2022
Historique:
received: 09 06 2020
revised: 12 10 2020
accepted: 13 10 2020
pubmed: 29 11 2020
medline: 3 2 2022
entrez: 28 11 2020
Statut: ppublish

Résumé

Where a person is unable to make medical decisions for themselves, law and practice allows others to make decisions on their behalf. This is common at the end of a person's life where decision-making capacity is often lost. A further, and separate, decision that is often considered at the time of death (and often preceding death) is whether the person wanted to act as an organ or tissue donor. However, in some jurisdictions, the lawful decision-maker for the donation decision (the 'donation decision-maker') is different from the person who was granted decision-making authority for medical decisions during the person's life. To date, little attention has been given in the literature to the ethical concerns and practical problems that arise where this shift in legal authority occurs. Such a change in decision-making authority is particularly problematic where premortem measures are suggested to maximise the chances of a successful organ donation. This paper examines this shift in decision-making authority and discusses the legal, ethical and practical implications of such frameworks.

Identifiants

pubmed: 33246994
pii: medethics-2020-106572
doi: 10.1136/medethics-2020-106572
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112-117

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: S-NT and DM were members of the Australia National Health and Medical Research Council’s (NHMRC) Organ and Tissue Working Committee.DM has received consultancy fees from the Australian Organ and Tissue Authority (AOTA). The views presented here are the authors’ own.

Auteurs

Shih-Ning Then (SN)

Australian Centre for Health Law Research, Faculty of Law, Queensland University of Technology, Brisbane, Queensland, Australia shih-ning.then@qut.edu.au.

Dominique E Martin (DE)

School of Medicine, Deakin University, Geelong, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH